Amy Law

Summary

Affiliation: Geisinger Medical Center
Country: USA

Publications

  1. ncbi request reprint Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck
    Amy Law
    Department of Hematology Oncology, Geisinger Medical Center, Danville, PA 17822, USA
    Int J Radiat Oncol Biol Phys 69:1361-8. 2007
  2. ncbi request reprint Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center
    Farid Fata
    Department of Hematology Oncology, Geisinger Medical Center, 100 N Academy Avenue, Danville, PA 17822, USA
    Cancer 94:1931-8. 2002
  3. ncbi request reprint Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen
    Nava Siegelmann-Danieli
    Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822 2001, USA
    Isr Med Assoc J 6:636-7. 2004
  4. ncbi request reprint Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications
    Robert E Brown
    Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA
    Ann Clin Lab Sci 36:421-6. 2006
  5. ncbi request reprint Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis
    Ping L Zhang
    Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17822 0131, USA
    Mod Pathol 18:924-32. 2005
  6. ncbi request reprint Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB
    Mingyue Lun
    Weis Center for Research, Geisinger Medical Center, 100 North Academy Ave, Danville, PA 17822, USA
    Ann Clin Lab Sci 35:251-8. 2005
  7. ncbi request reprint Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
    David P Steensma
    Mayo Clinic and Mayo Foundation, Rochester 55905, USA
    J Clin Oncol 24:1079-89. 2006
  8. ncbi request reprint Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma
    Robert E Brown
    Department of Pathology, University of Texas Houston Medical School, 6431 Fannin Street, Room 2 286, Houston, TX 77030, USA
    Ann Clin Lab Sci 36:273-82. 2006

Detail Information

Publications8

  1. ncbi request reprint Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck
    Amy Law
    Department of Hematology Oncology, Geisinger Medical Center, Danville, PA 17822, USA
    Int J Radiat Oncol Biol Phys 69:1361-8. 2007
    ..To report long-term data from a prospective trial of subcutaneous (s.c.) amifostine in patients who received chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN)...
  2. ncbi request reprint Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center
    Farid Fata
    Department of Hematology Oncology, Geisinger Medical Center, 100 N Academy Avenue, Danville, PA 17822, USA
    Cancer 94:1931-8. 2002
    ..Although the benefit from adjuvant chemotherapy has been established clearly in patients with Stage III colon carcinoma, the degree to which elderly patients with colon carcinoma can tolerate such therapy generally has remained unknown...
  3. ncbi request reprint Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen
    Nava Siegelmann-Danieli
    Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822 2001, USA
    Isr Med Assoc J 6:636-7. 2004
  4. ncbi request reprint Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications
    Robert E Brown
    Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA
    Ann Clin Lab Sci 36:421-6. 2006
    ..Furthermore, such constitutive activation of the NF-kappaB pathway helps to explain some of the tumor biology and supports the incorporation of NF-kappaB pathway inhibitors into the treatment of GBM...
  5. ncbi request reprint Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis
    Ping L Zhang
    Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17822 0131, USA
    Mod Pathol 18:924-32. 2005
    ....
  6. ncbi request reprint Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB
    Mingyue Lun
    Weis Center for Research, Geisinger Medical Center, 100 North Academy Ave, Danville, PA 17822, USA
    Ann Clin Lab Sci 35:251-8. 2005
    ..p-kappaB complex. The free p-NF-kappaB can then be translocated to the nucleus where it effects transcriptional activation of genes leading to the synthesis of proteins that are generally pro-growth and anti-apoptosis...
  7. ncbi request reprint Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
    David P Steensma
    Mayo Clinic and Mayo Foundation, Rochester 55905, USA
    J Clin Oncol 24:1079-89. 2006
    ..To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia...
  8. ncbi request reprint Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma
    Robert E Brown
    Department of Pathology, University of Texas Houston Medical School, 6431 Fannin Street, Room 2 286, Houston, TX 77030, USA
    Ann Clin Lab Sci 36:273-82. 2006
    ..In conclusion, these morphoproteomic and pharmacoproteomic data collectively provide a rationale for selecting mTOR effectors as therapeutic targets in HNSCC...